Kinetics of hepatitis C virus load during hemodialysis: Novel perspectives

Journal of Nephrology

Volumn 16, Issue 4, 2003, Pages 467-475

  Fabrizi, Fabrizio ^a,b   Bunnapradist, Suphamai ^a   Lunghi, Giovanna ^b   Martin, Paul ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dialysis; Hepatitis C; Viremia

Indexed keywords

ANTIVIRUS AGENT; HEPARIN; INTERFERON; NAFAMSTAT MESILATE; POLYSULFONE; VIRUS RNA;

ADSORPTION; DIALYSATE; DIALYSIS MEMBRANE; DISEASE COURSE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE DEFICIENCY; IN VITRO STUDY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; KINETICS; LIVER DISEASE; NONHUMAN; PREDICTION; PREVALENCE; REVIEW; RISK; UREMIA; VIREMIA; VIRUS LOAD;

FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; KINETICS; MALE; RENAL DIALYSIS; RISK ASSESSMENT; RNA, VIRAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VIRAL LOAD; VIREMIA;

EID: 1642476682     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Tokars JI, Frank M, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2000. Semin Dial 2002; 15: 162-71.
2. Stehman-Breen CO, Emerson S, Gretch D, Johnson RJ. Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis 1998; 32: 629-34.
3. Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of anti-hepatitis C virus antibody-positive on regular hemodialysis therapy. J Am Soc Nephrol 2000; 11: 1896-1902.
4. Espinosa M, Martin-Malo A, de Lara MA, Alijama P. Risk of death and liver cirrhosis in anti-HCV positive long-term haemodialysis patients. Nephrol Dial Transplant 2001; 16: 1669-74.
5. Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, Wolfe RA, Jones E, Disney AP, Briggs D, McCredie M, Boyle P. Cancer in patients on dialysis for end-stage renal disease: An international collaborative study. Lancet 1999; 354: 93-99.
6. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002; 36: 3-10.
7. Seef LB, Hoofnagle JH. National Institute of Health Consensus Development Conference: Management of hepatitis C: 2002. Hepatology 2002; 36 (suppl 5): S1-20.
8. Bain GV. Effect of HCV viral dynamics on treatment design: Lessons learned from HIV. Am J Gastroenterol 2001; 96: 2818-28.
9. Fabrizi F, Martin P, Lunghi G, Locatelli F. Membrane compatibility, flux and HCV infection in dialysis patients: Newer evidence. Int J Artif Organs 2000; 23: 296-304.
10. Broumand B, Shamshirsaz AA, Kamgar M, Hashemi R, Aiazi F, Bekheirnia M, Boozary Z, Komeilian Z, Shamshirsaz AH, Tabatabaiee MR, Broumand V. Prevalence of hepatitis C infection and its risk factors in hemodialysis patients in Tehran: Preliminary report from the 'Effect f dialysis unit isolation on the incidence of hepatitis C in dialysis patients' project. Saudi J Kidney Dis Transplant 2002; 13: 467-72.
11. Valtuille R, Moretto H, Lef L, Rendo P, Fernando JL. Decline of high hepatitis C virus prevalence in a hemodialysis unit with no isolation measures during a 6-year follow-up. Clin Nephrol 2002; 57: 371-5.
12. Jaiswal SK, Chitnis DS, Salgia P, Sepaha A, Pandit CS. Prevalence of hepatitis viruses among chronic renal failure patients on hemodialysis in Central India. Dial Transplant 2002; 31: 234-40.
13. Yilmaz ME, Kara IH, Sari Y, Duzen S, Usul Y, Isikoglu B. Seroprevalence and risk factors of HCV in dialysis patients in a university hemodialysis center of southeast Anatolia, Turkey. Dial Transplant 2001; 30: 748-55.
14. Saxena AK, Panhotra BR, Naguib M, Aboras MN, Sundaram DS, Venkateshappa CK, Khan WU. Prevalence of hepatitis C antibodies among hemodialysis patients in Al-Hasa Region of Saudi Arabia. Saudi J Kidney Dis Transplant 2001; 12: 562-5.
15. Petrosillo N, Gilli P, Serraino D, Dentico P, Mele A, Ragni P, Puro V, Casalino C, Ippolito G, for the Collaborative Group. Prevalence of infected patients and understanding have a role in hepatitis C virus transmission in dialysis. Am J Kidney Dis 2001; 37: 1004-10.
16. Mizuno M, Higuchi T, Yanai M, Kanmatsuse K, Esumi M. Dialysis-membrane-dependent reduction and adsorption of circulating hepatitis C virus during hemodialysis. Nephron 2002; 91: 235-42.
17. Noiri E, Nakao A, Oya A, Fujita T, Kimura S. Hepatitis C virus in blood and dialysate in hemodialysis. Am J Kidney Dis 2001; 37: 38-42.
18. Wang JT, Wang TH, Sheu JC, Lin SM, Lin JT, Chen DS. Effects of anticoagulants and storage of blood samples on the polymerase chain reaction assay for hepatitis C virus. J Clin Microbiol 1992; 30: 750-3.
19. Furukawa K, Bhavandanan VP. Influences of anionic polysaccharides on DNA synthesis in isolated nuclei and by DNA polymerase alpha: Correlation of observed effects with properties of the polysaccharides. Biochem Biophys Acta 1983; 740: 466-75.
20. DiCioccio RA, Srivastava BI. Inhibition of deoxynuceotide-polymerizing enzyme activities of human cells and of simia sarcoma virus by heparin. Cancer Res 1978; 38: 2402-7.
21. Akizawa T, Koshikawa S, Ota K, Kazama M, Minura N, Hirasawa Y. Nafamostat mesilate: A regional anticoagulant for hemodialysis in patients at high risk for bleeding. Nephron 1993; 64: 376-81.
22. Okuda K, Hayashi Y, Yokozeki K, Irie Y. Destruction of hepatitis C virus particles by haemodialysis (letter). Lancet 1996; 347: 909-10.
23. Adorati M, Pipan C, Botta G. Membrane compatibility and clearance of hepatitis C virus in chronic dialysis patients (letter). Nephron 1999; 82: 358.
24. Angelini C, Badalamenti S, Lunghi G, Sampietro M, Finazzi S, Ponticelli C, Graziani G. Evidence against hepatitis C virus trapping in dialysis membranes (letter). Nephrol Dial Transplant 2002; 17: 317-8.
25. Angelico M, Morosetti M, Passalacqua S, Chiappini MG, Botta S, Ombres D, Splendiani G, Casciani CU. Low levels of hepatitis C virus RNA in blood of infected patients under maintenance haemodialysis with high-biocompatibility high-permeability filters. Dig Liver Dis 2000; 32:724-8.
26. Manzini P, Amore A, Brunetto MR, Martina G, Verme G, Bonino F, Coppo R. Is hepatitis C virus RNA detectable in dialysis ultrafiltrate? (letter). Nephron 1996; 72: 102-3.
27. Lindsay KL, El-Shahawy M, Milstein S, Valinluck B, Rajan S, Lagier R, Sanchez-Pescador R. HCV RNA levels are lowered during hemodialysis in patients with chronic hepatitis C (abstract). Hepatology 1994; 20: 570.
28. Badalamenti S, Lunghi G, Como G, Sampietro M, Finazzi S, Corbetta N, Valenti G, Buccianti G, Graziani G. Destruction of hepatitis C virus (HCV) during hemodialysis (abstract) J Am Soc Nephrol 1996; 7: 1438.
29. Furusyo N, Hayashi J, Ariyama I, Sawayama Y, Etoh Y, Shigematsu M, Kashiwagi S. Maintenance hemodialysis decreases serum hepatitis C virus (HCV) RNA levels in hemodialysis patients with chronic HCV infection. Am J Gastroenterol 2000; 95: 490-6.
30. Zeuzem S, Schmidt JM, Lee JH, Ruster B, Roth WK. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996; 23: 366-71.
31. Sterling KR, Sanyal AJ, Luketic VA, Stravitz RT, King AL, Post AB, Mills AS, Contos MJ, Shiffman ML. Chronic hepatitis C infection in patients with end-stage renal disease: Characterization of liver histology and viral load in patients awaiting renal transplantation. Am J Gastroenterol 1999; 94: 3576-82.
32. Alric L, Di-Martino V, Selves J, Cacoub P, Charlotte F, Reynaud D, Piette JC, Peron JM, Vinel JP, Durand D, Izopet J, Poynard T, Duffaut M, Rostaing L. Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology 2002; 123: 1494-9.
33. Gretch D, dela Rosa C, Carithers RL, Willson RA, Williams B, Corey L. Assessment of hepatitis C viremia using molecular amplification technologies. Correlations and clinical implications. Ann Intern Med 1995; 123: 321-9.
34. Fabrizi F, Martin P, Dixit V, Brezina M, Cole MJ, Gerosa S, Vinson S, Mousa M, Gitnick G. Quantitative assessment of HCV load in chronic hemodialysis patients: A cross-sectional survey. Nephron 1998; 80: 428-33.
35. Gretch D, Corey L, Wilson J, dela Rosa C, Willson R, Carithers R, Busch M, Hart J, Sayers M, Han J. Assessment of hepatitis C virus RNA levels by quantitative competitive RNA polymerase chain reaction: High-titer viremia correlates with advanced stage of disease. J Infect Dis 1994; 169: 1219-25.
36. Martin P, Carter D, Fabrizi F, Dixit V, Conrad A, Artinian L, Peacock V, Han S, Wilkinson A, Lassman C, Danovitch G. Histopathological features of hepatitis C in renal transplant candidates. Transplantation 2000; 69: 1479-84.
37. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36 (suppl 1): S35-46.
38. Yuki N, Hayashi N, Kasahara A, Hagiwara H, Takehara T, Oshita M, Katayama K, Fusamoto H, Kamada T. Pretreatment viral load and response to prolonged interferon-α course for chronic hepatitis C. J Hepatol 1995; 22: 457-63.
39. Yamada G, Takatani M, Kishi F, Takahashi M, Doi T, Tsuji T, Shin S, Tanno M, Urdea MS, Kolberg JA. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology 1995; 22: 1351-4.
40. Mizokami M, Orito E, Gibo Y, Suzuki KI, Ohba KI, Lau JY. Genotype, serum level of hepatitis C virus RNA and liver histology as predictors of response to interferon-α 2a therapy in Japanese patients with chronic hepatitis C. Liver 1996; 16: 23-7.
41. Toyoda H, Nakano S, Kumada T, Takeda I, Sugimaya K, Osada T, Kiruyama S, Orito E, Mizokami M. Comparison of serum hepatitis C virus RNA concentration by branched DNA probe assay with competitive reverse transcription polymerase chain reaction as a predictor of response to interferon-alfa therapy in chronic hepatitis C patients. J Med Virol 1996; 48: 354-9.
42. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, Descombs I, Le Breton V, Milotova V, Benhamou JP, Erlinger S. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22: 1050-6.
43. Fanning L, Kenny E, Sheehan M, Cannon B, Whelton M, O'Connell J, Collins JK, Shanahan F. Viral load and clinicopathological features of chronic hepatitis C (1b) in a homogeneous patient population. Hepatology 1999; 29: 904-7.
44. Kato N, Yokosuka O, Hosoda K, Ito Y, Ohto M, Omata M. Quantification of hepatitis C virus by competitive reverse transcription-polymerase chain reaction: Increase of the virus in advanced liver disease. Hepatology 1993; 18: 16-20.
45. Magrin S, Craxi A, Fabiano C, Simonetti RG, Fiorentino G, Marino L, Diquattro O, Di Marco V, Loiacono O, Volpes R, Almasio P, Urdea MS, Neuwald P, Sanchez-Pescador R, Detmer J, Wilber JC, Pagliaro L. Hepatitis C viraemia in chronic liver disease. Relationship to interferon-alpha or corticosteroid treatment. Hepatology 1994; 9: 273-9.
46. Farci P, Alter HJ, Wong D, Miller RH, Shih JW, Jett B, Purcell RH. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 1991; 325: 98-104.
47. Nguyen TT, Sedghi-Vaziri A, Wilkes LB, Mondala T, Pockros PJ, Lindsay KL, McHutchison JG. Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. J Viral Hepat 1996; 3: 75-8.
48. Fanning L, Kenny-Walsh E, Levis J, Chooudhury KR, Cannon B, Sheehan M, Whelton M, Shanahan F. Natural fluctuations of hepatitis C viral load in a homogeneous patient population: A prospective study. Hepatology 2000; 31: 225-9.
49. Fabrizi F, Martin P, Dixit V, Brezina M, Cole MJ, Vinson S, Mousa M, Gitnick G. Biological dynamics of viral load in hemodialysis patients with hepatitis C virus. Am J Kidney Dis 2000; 35: 122-9.
50. Halfon P, Khiri H, Feryn JM, Sahada C, Chanas M, Ouzan D. Prospective virological follow-up of hepatitis C infection in a haemodialysis unit. J Viral Hepat 1998; 5: 115-21.
51. Yuasa T, Ishikawa G, Manabe S, Sekiguchi S, Takeuchi K, Miyamura T. The particle size of hepatitis C virus estimated by filtration through microporus regenerated cellulose fibre. J Gen Virol 1991; 72: 2021-4.
52. Lombardi M, Cerrai T, Dattolo P, Pizzarelli F, Michelassi S, Maggiore Q, Zignego AL. Is the dialysis membrane a safe barrier against HCV infection? (letter). Nephrol Dial Transplant 1995; 10: 578-9.
53. Valtuille R, Fernandez JL, Berridi J, Moretto H, Del Pino N, Rendo P, Lef L. Evidence of hepatitis C virus passage across dialysis membrane. Nephron 1998; 80: 194-6.
54. Sampietro M, Graziani G, Badalamenti S, Salvadori S, Caldarelli R, Como G, Fiorelli G. Detection of hepatitis C virus in dialysate and in blood ultrafiltrate of HCV-positive patients (letter). Nephron 1994; 68: 140.
55. Furusyo N, Hayashi J, Kakuda K, Ariyama I, Kanamoto-Tanala Y, Shimizu C, Etoh Y, Shigematsu M, Kashiwagi S. Acute hepatitis C among Japanese hemodialysis patients: A prospective 9-year study. Am J Gastroenterol 2001; 96: 1592-600.
56. Caramelo C, Navas S, Alberola ML, Bermejillo T, Reyero A, Carreno V. Evidence against transmission of hepatitis C virus through hemodialysis ultrafiltrate and peritoneal fluid. Nephron 1994; 66: 470-3.
57. Hubmann R, Zazgornick J, Gabriel C, Garbeis B, Blaunhut B. Hepatitis C virus: Does it penetrate the hemodialysis membrane? PCR analysis of hemodialysis ultrafiltrate and whole blood. Nephrol Dial Transplant 1995; 10: 541-2.
58. Noiri E, Masaki I, Fujino K, Tsuchiya M. Efficacy of a continuous extraction method for monitoring hemodialysis ultrafiltrate. ASAIO J 2000; 46: 461-3.
59. Garcia-Valdecasas J, Garcia F, Bernal MC, Garcia F Jr, Maroto MC, Cerezo S. Can HCV-RNA pass through dialysis (HD) membranes? (abstract). J Am Soc Nephrol 1998; 9: 209A.
60. Degos F, Pol S, Chaix ML, Laffitte V, Buffet C, Bernard PH, Degott C, Carnot F, Chaumet Riffaud P, Chevret S. The tolerance and efficacy of interferon-α in haemodialysis patients with HCV infection: A multicentre, prospective study. Nephrol Dial Transplant 2001; 16: 1017-23.
61. Graziani G, Badalamenti S, Sampietro M, Catania A, Lunghi G, Como G, Finazzi S, Angelini C, Fiorelli G, Ponticelli C. Produzione endogena di α-interferon (α-IFN) durante emodialisi (ED) in pazienti HCV positivi (abstract). G Ital Nefrol 1998; 15: 191.
62. Rostaing L, Chatelut E, Payen JL, Izopet J, Thalamas C, Ton-That H, Pascal JP, Durand D, Canal P. Pharmacokinetics of alpha IFN-2b in chronic hepatitis C virus in patients undergoing chronic hemodialysis or with normal renal function: Clinical implications. J Am Soc Nephrol 1998; 9: 2344-8.
63. Uchihara M, Izumi N, Sakai Y, Yauchi T, Miyake S, Sakai T, Akiba T, Marumo F, Sato C. Interferon therapy of chronic hepatitis C in hemodialysis patients: Increased serum levels of interferon. Nephron 1998; 80: 51-6.
64. Hayashi H, Okuda K, Yokosuka O, Kobayashi S, Yokozeki K, Ohtake Y, Irie Y. Adsorption of hepatitis C virus particles onto the dialyzer membrane. Artif Organs 1997; 21: 1056-9.
65. Badalamenti S, Lunghi G, Como G, Sampietro M, Finazzi S, Corbetta N, Valenti G, Buccianti G, Graziani G. Destruction of hepatitis C virus (HCV) during hemodialysis (abstract). Am Soc Nephrol 1996; 7: 1438.
66. Clark WR, Hamburger RJ, Lysaght MJ. Effect of membrane composition and structure on solute removal and biocompatibility in hemodialysis. Kidney Int 1999; 56: 2005-15.
67. Clark WR, Macias WL, Molitoris BA, Wang NH. Plasma protein adsorption to highly permeable hemodialysis membranes. Kidney Int 1995; 48: 481-8.